Ansa Biotechnologies: Funding, Investors & Team (Sep 2026)
Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerate innovation in biological research and engineering.
Ansa Biotechnologies has raised $121M across 3 funding rounds on record, the most recent a Series B of $45.2M announced in Oct 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ansa Biotechnologies Company Profile and Key Stats
Latest funding round on record: Oct 2025.
Ansa Biotechnologies Funding Rounds
Ansa Biotechnologies raised $7.9M in an undisclosed round announced in Sep 2020.
1.6 years later, a Series A of $68.0M was announced in Apr 2022.
3.5 years later, a Series B of $45.2M was announced in Oct 2025.
Ansa Biotechnologies Founders and Leadership Team
Contact details for the Ansa Biotechnologies team: 2 of 3 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Ansa Biotechnologies Funding Compared to Other Biotechnology Startups
Ansa Biotechnologies' latest round of $45.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ansa Biotechnologies in Biotechnology and Emeryville
Companies Similar to Ansa Biotechnologies
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Ansa Biotechnologies Funding FAQs
What does Ansa Biotechnologies do?
Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerate innovation in biological research and engineering.
How much funding has Ansa Biotechnologies raised?
Ansa Biotechnologies has raised $121M across 3 rounds on record. The most recent is a Series B of $45.2M announced in Oct 2025.
When did Ansa Biotechnologies last raise funding?
Ansa Biotechnologies' most recent funding round on record is a Series B of $45.2M, announced in Oct 2025.
Who founded Ansa Biotechnologies?
FundedIQ lists Jared Ellefson (Founder) at Ansa Biotechnologies.
Who is the CEO of Ansa Biotechnologies?
Daniel Arlow is listed as CEO at Ansa Biotechnologies.
Where is Ansa Biotechnologies headquartered?
Ansa Biotechnologies is based in Emeryville, California, United States.
How many employees does Ansa Biotechnologies have?
Ansa Biotechnologies is in the 11-50 employee band.
How does Ansa Biotechnologies' funding compare to other Biotechnology startups?
Ansa Biotechnologies' latest round of $45.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Ansa Biotechnologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ansa Biotechnologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.